Please login to the form below

Not currently logged in
Email:
Password:

AbbVie and Roche to launch Venclexta within a week

FDA approves first-in-class BCL-2 inhibitor to treat chronic lymphocytic leukaemia patients
AbbVie

The FDA has approved AbbVie and Roche's Venclexta, a first-in-class BCL-2 inhibitor that has been given the nod to treat a subgroup of chronic lymphocytic leukaemia (CLL) patients.

The US regulator cleared Venclexta (venetoclax) as a treatment for CLL patients who carry a mutation known as a 17p deletion and have been treated with at least one prior therapy after a review of just three months. AbbVie and Roche say they plan to start shipping the new product within the next week.

CLL is a slow-progressing cancer of the bone marrow and blood and is the most common leukaemia diagnosed in adults in western countries, with around 15,000 new cases a year in the US.

The 17p deletion - which results in the loss of a tumour suppressor gene - is found in around 10% of early CLL cases but upwards of 20% among patients with more advanced disease. A companion diagnostic developed by Abbott is already available to identify patients with the mutation.

The FDA approval is based on a clinical trial involving 106 previously-treated patients with 17p deletion-positive CLL who took Venclexta orally once-a-day in escalating doses. The results showed that 80% of trial participants experienced a complete or partial remission of their cancer.

Analysts have suggested that Venclexta could become a blockbuster product for Roche and AbbVie with sales in excess of $1.5bn a year, thanks in part to a price tag of around $110,000 for the first 12 months' treatment but also other potential uses in non-Hodgkin's lymphoma (NHL), acute myeloid leukaemia and multiple myeloma.

The two companies will co-market the new product in the US while AbbVie has sole marketing rights in other markets.

Venclexta will compete in the market with other new therapies for CLL, including Johnson & Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' PI3 kinase inhibitor Zydelig (idelalisib), which is specifically indicated for use in 17p deletion-positive patients.

Both Imbruvica and Zydelig were approved for CLL in 2014 and have been tipped to become $1bn-plus products at peak. J&J reported $689m in Imbruvica sales in 2015, while Zydelig made $132m.

Meanwhile, Roche is already a player in the first-line CLL setting with Gazyva (obinutuzumab), which was approved in 2013.

Article by
Phil Taylor

12th April 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics